3-(1-(4-carbamoyl-2-chlorophenyl)-5-(4-methoxyphenyl)-1H-pyrrol-2-yl)propanoic acid | 1208315-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-(1-(4-carbamoyl-2-chlorophenyl)-5-(4-methoxyphenyl)-1H-pyrrol-2-yl)propanoic acid
• 英文别名: 3-[1-(4-Carbamoyl-2-chlorophenyl)-5-(4-methoxyphenyl)pyrrol-2-yl]propanoic acid
• CAS: 1208315-33-6
• 化学式: C₂₁H₁₉ClN₂O₄
• 分子量: 398.846
• InChiKey: CZRNQAKJYPCPSI-UHFFFAOYSA-N

物化性质

• 沸点：
  605.6±55.0 °C(predicted)
• 密度：
  1.33±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(2-furyl)-1-(4-methoxyphenyl)propen-1-one 在 水 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 生成 3-(1-(4-carbamoyl-2-chlorophenyl)-5-(4-methoxyphenyl)-1H-pyrrol-2-yl)propanoic acid
  参考文献：
  名称：

  Discovery of S-Nitrosoglutathione Reductase Inhibitors: Potential Agents for the Treatment of Asthma and Other Inflammatory Diseases

  摘要：

  S-Nitrosoglutathione reductase (GSNOR) regulates S-nitrosothiols (SNOs) and nitric oxide (NO) in vivo through catabolism of S-nitrosoglutathione (GSNO). GSNOR and the anti-inflammatory and smooth muscle relaxant activities of SNOs, GSNO, and NO play significant roles in pulmonary, cardiovascular, and gastrointestinal function. In GSNOR knockout mice, basal airway tone is reduced and the response to challenge with bronchoconstrictors or airway allergens is attenuated. Consequently, GSNOR has emerged as an attractive therapeutic target for several clinically important human diseases. As such, small molecule inhibitors of GSNOR were developed. These GSNOR inhibitors were potent, selective, and efficacious in animal models of inflammatory disease characterized by reduced levels of GSNO and bioavailable NO. N6022, a potent and reversible GSNOR inhibitor, reduced bronchoconstriction and pulmonary inflammation in a mouse model of asthma and demonstrated an acceptable safety profile. N6022 is currently in clinical development as a potential agent for the treatment of acute asthma.

  DOI：

  10.1021/ml200045s

文献信息

• [EN] NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS<br/>[FR] NOUVEAUX INHIBITEURS PYRROLE DE S-NITROSOGLUTATHIONE RÉDUCTASE EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2010019903A1

  公开（公告）日：2010-02-18

  The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

  本发明涉及S-亚硝基谷胱甘肽还原酶（GSNOR）的抑制剂，包括这样的GSNOR抑制剂的制药组合物，以及制备和使用这些组合物的方法。
• Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents
  申请人：Wasley Jan

  公开号：US20110144110A1

  公开（公告）日：2011-06-16

  The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

  本发明涉及S-亚硝基谷胱甘肽还原酶（GSNOR）的抑制剂，包括这种GSNOR抑制剂的药物组合物，以及制备和使用它们的方法。
• 治療薬剤としての、Ｓ−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤
  申请人：エヌサーティー・ファーマシューティカルズ,エルエルシー

  公开号：JP2012500216A

  公开（公告）日：2012-01-05

  本発明は、Ｓ−ニトロソグルタチオンレダクターゼ（ＧＳＮＯＲ）の阻害剤、そのようなＧＳＮＯＲ阻害剤を含んでなる医薬組成物、及びそれらを作製して使用する方法へ向けられる。

  本发明涉及 S-亚硝基谷胱甘肽还原酶（GSNOR）的抑制剂、包含这种 GSNOR 抑制剂的药物组合物以及制造和使用它们的方法。
• NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS
  申请人：N30 Pharmaceuticals, LLC

  公开号：EP2318006A1

  公开（公告）日：2011-05-11
• Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
  申请人：Goessling Wolfram

  公开号：US20140135396A1

  公开（公告）日：2014-05-15

  The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide.